An in-depth analysis of the current exchange rate dynamics of the Indian...
Fundamentals for Poly Medicure Limited
Last Updated:
2025-09-04 19:45
Overall Fundamental outlook
Business Operations:
Sector: Healthcare Industry: Medical Instruments & Supplies
Poly Medicure Limited manufactures and sells medical devices in India and internationally. It offers infusion devices, such as I.V. cannulas, mid line catheters, arterial cannula, three way stop cocks, I.V. infusion sets, manifolds, safety winged infusion sets, T-type extension sets, stylet/mandrin with luer locks, vial access spikes, measured volume fluid administration sets, extension lines, central venous catheters, CVP manometers, needle free connectors, pre filled syringes, vascular accesses, and blood administration sets. The company also provides nasogastric and infant feeding tubes, gastro-duodenal feeding tubes, and umbilical catheters; urine collection bags, foley balloon catheters, irrigation sets, urine drainage catheters, and urine collection bags with measured volume meters; and endotracheal and tracheostomy tubes, mucus extractors, ventilator circuits, bain circuits, catheter mounts, spinal needles, HME filters, and laryngeal mask airways. It offers oncology products; endo bronchial suction catheters, oxygen catheters, respiratory exercisers, nasal oxygen cannulas, oro-pharyngeal airways, variable concentration masks, oxygen mask with reservoirs, fixed concentration masks, and aerosol therapy masks; and dialyzers, blood lines, dialysis systems, fistula needles, haemodialysis catheters, and peritoneal dialysis and transfusion sets. The company provides closed wound suction units, under water seal drainage systems, high pressure vacuum bottles, yankauer suction sets, and thoracic drainage catheters; blood collection tubes, safety blood collection sets, blood collection needles, ESR pipettes, and luer adaptors; blood bag systems; face protective shields, polymasks, and viral transport medium kits; and insulin syringes, sputum collectors, dry brushes, umbilical cord clamps, luer locks, cannula fixators, injection stoppers, luer lock injection sites, universal caps, and ECG electrodes. The company was incorporated in 1995 and is based in New Delhi, India.
Revenue projections:
Revenue projections for POLYMED POLYMED's revenues are expected to fall below last year's, and this forecast tends to raise concerns among investors. A revenue drop can negatively impact the company's profitability, making investors more cautious about their positions due to the risks of declining financial performance.
Financial Ratios:
currentRatio
5.179000
forwardPE
38.380394
debtToEquity
6.517000
earningsGrowth
0.253000
revenueGrowth
0.166000
grossMargins
0.667820
operatingMargins
0.223290
trailingEps
34.150000
forwardEps
7.680000
With a current ratio of 5.179, POLYMED has the liquidity needed to easily service its short-term debt. The company's cash reserves and current assets are sufficient, indicating that POLYMED is in a strong position to meet its immediate financial obligations without difficulty. POLYMED's positive earnings and revenue growth suggest that the company is poised for business expansion. This financial strength indicates that POLYMED is expected to continue growing, with rising profits and sales contributing to its long-term success. POLYMED's positive gross and operating margins highlight its strong profitability. The company's ability to control costs while generating revenue indicates efficient operations and a healthy financial position. POLYMED's forward EPS falling below its trailing EPS suggests the company is expected to be less profitable this year. This signals a potential decline in earnings, which may raise concerns about POLYMED's financial future.
Price projections:
Price projections for POLYMED Price projections for POLYMED have gradually risen over time, signaling increased optimism about the company's future prospects. This steady upward revision reflects growing confidence in POLYMED's market potential.
Recommendation changes over time:
Recommendations trend for POLYMED
With no clear buy or sell ratings for POLYMED, analysts have painted a mixed picture of the stock. This ambiguity may prompt investors to consider alternative market signals and undertake further research before deciding how to proceed with their investments.
DISCLAIMER: We provide information and our musings based on events, but nothing on this site can be considered professional advice of any kind.
The article discusses the implications of the Eurozone CPI at 2.1% regarding...
By clicking "Accept", you agree to the storing of cookies on your device to enhance site navigation, analyze site usage and assist in our tailored marketing efforts.